N-Acetylcysteine to Combat COVID-19: An Evidence Review

Zhongcheng Shi,1,2 Carlos A Puyo3 1Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; 2Department of Pathology, Texas Children’s Hospital, Houston, TX, USA; 3Department of Anesthesia and Critical Care, Holy Family Hospital, Steward Health Care, Methuen, M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shi Z, Puyo CA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	n-acetylcysteine sars-cov-2 covid-19 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/7462d7358ee64346ab9b8d5838d7d199
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7462d7358ee64346ab9b8d5838d7d199
record_format	dspace
spelling	oai:doaj.org-article:7462d7358ee64346ab9b8d5838d7d1992021-12-02T11:22:06ZN-Acetylcysteine to Combat COVID-19: An Evidence Review1178-203Xhttps://doaj.org/article/7462d7358ee64346ab9b8d5838d7d1992020-11-01T00:00:00Zhttps://www.dovepress.com/n-acetylcysteine-to-combat-covid-19-an-evidence-review-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XZhongcheng Shi,1,2 Carlos A Puyo3 1Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; 2Department of Pathology, Texas Children’s Hospital, Houston, TX, USA; 3Department of Anesthesia and Critical Care, Holy Family Hospital, Steward Health Care, Methuen, MA, USACorrespondence: Zhongcheng Shi Tel +1- 832-824-0814Email zhongchs@bcm.eduAbstract: The novel coronavirus disease (COVID-19) is caused by a virus (SARS-Cov-2) and is known for inducing multisystem organ dysfunction associated with significant morbidity and mortality. Current therapeutic strategies for COVID-19 have failed to effectively reduce mortality rate, especially for elderly patients. A newly developed vaccine against SARS-Cov-2 has been reported to induce the production of neutralizing antibodies in young volunteers. However, the vaccine has shown limited benefit in the elderly, suggesting an age-dependent immune response. As a result, exploring new applications of existing medications could potentially provide valuable treatments for COVID-19. N-acetylcysteine (NAC) has been used in clinical practice to treat critically ill septic patients, and more recently for COVID-19 patients. NAC has antioxidant, anti-inflammatory and immune-modulating characteristics that may prove beneficial in the treatment and prevention of SARS-Cov-2. This review offers a thorough analysis of NAC and discusses its potential use for treatment of COVID-19.Keywords: N-acetylcysteine, SARS-Cov-2, COVID-19Shi ZPuyo CADove Medical Pressarticlen-acetylcysteinesars-cov-2covid-19Therapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 16, Pp 1047-1055 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	n-acetylcysteine sars-cov-2 covid-19 Therapeutics. Pharmacology RM1-950
spellingShingle	n-acetylcysteine sars-cov-2 covid-19 Therapeutics. Pharmacology RM1-950 Shi Z Puyo CA N-Acetylcysteine to Combat COVID-19: An Evidence Review
description	Zhongcheng Shi,1,2 Carlos A Puyo3 1Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; 2Department of Pathology, Texas Children’s Hospital, Houston, TX, USA; 3Department of Anesthesia and Critical Care, Holy Family Hospital, Steward Health Care, Methuen, MA, USACorrespondence: Zhongcheng Shi Tel +1- 832-824-0814Email zhongchs@bcm.eduAbstract: The novel coronavirus disease (COVID-19) is caused by a virus (SARS-Cov-2) and is known for inducing multisystem organ dysfunction associated with significant morbidity and mortality. Current therapeutic strategies for COVID-19 have failed to effectively reduce mortality rate, especially for elderly patients. A newly developed vaccine against SARS-Cov-2 has been reported to induce the production of neutralizing antibodies in young volunteers. However, the vaccine has shown limited benefit in the elderly, suggesting an age-dependent immune response. As a result, exploring new applications of existing medications could potentially provide valuable treatments for COVID-19. N-acetylcysteine (NAC) has been used in clinical practice to treat critically ill septic patients, and more recently for COVID-19 patients. NAC has antioxidant, anti-inflammatory and immune-modulating characteristics that may prove beneficial in the treatment and prevention of SARS-Cov-2. This review offers a thorough analysis of NAC and discusses its potential use for treatment of COVID-19.Keywords: N-acetylcysteine, SARS-Cov-2, COVID-19
format	article
author	Shi Z Puyo CA
author_facet	Shi Z Puyo CA
author_sort	Shi Z
title	N-Acetylcysteine to Combat COVID-19: An Evidence Review
title_short	N-Acetylcysteine to Combat COVID-19: An Evidence Review
title_full	N-Acetylcysteine to Combat COVID-19: An Evidence Review
title_fullStr	N-Acetylcysteine to Combat COVID-19: An Evidence Review
title_full_unstemmed	N-Acetylcysteine to Combat COVID-19: An Evidence Review
title_sort	n-acetylcysteine to combat covid-19: an evidence review
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/7462d7358ee64346ab9b8d5838d7d199
work_keys_str_mv	AT shiz nacetylcysteinetocombatcovid19anevidencereview AT puyoca nacetylcysteinetocombatcovid19anevidencereview
_version_	1718395945510502400

N-Acetylcysteine to Combat COVID-19: An Evidence Review

Ejemplares similares